Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Cytarabine + Onvansertib
Indication/Tumor Type acute myeloid leukemia
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable Cytarabine + Onvansertib Phase I Actionable In a Phase Ib trial, Onvansertib (PCM-075) and low-dose Cytosar-U (cytarabine) combination therapy resulted in an overall response rate of 13% (2/15) in patients with relapsed or refractory acute myeloid leukemia, with 1 patient achieving a complete remission without hematologic recovery, and 25% (3/12) of the evaluable patients achieved a >=50% reduction of bone marrow blasts (PMID: 32998961; NCT03303339). 32998961
PubMed Id Reference Title Details
(32998961) A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Full reference...